Immunoglobulins in COVID-19 pneumonia: from the acute phase to the recovery phase

Table 2 Baseline comorbidities of the COVID-19 study cohort and COVID-19 infection treatment used classified by pneumonia

Variables	No Pneumonia^a (WHO 1) (n = 24)	Pneumonia^b (WHO 2–7) (n = 228)	P-value^c
Comorbidities—no. (%)
Obesity	10 (23.8)	123 (38)	0.528
Diabetes Mellitus (DM)	7 (16.7)	67 (20.7)	0.353
Hypertension (HTA)	15 (35.7)	148 (45.7)	0.145
Dyslipidemia (DLP)	10 (23.8)	113 (34.9)	0.103
Cardiovascular diseases (CVD)	7 (16.7)	38 (11.7)	0.244
Respiratory diseases	5 (11.9)	32 (9.9)	0.426
Cancer	6 (14.3)	35 (10.8)	0.324
COVID-19 treatment
Oxygen requirement	0 (0)	28 (12.3)	0.042
Hydroxychloroquine	0 (0)	22 (9.6)	0.104
Azithromycin	3 (12.5)	142 (62.2)	< 0.001
Kaletra	0 (0)	16 (7)	0.171
Tocilizumab	0(0)	12 (5.3)	0.093
Interferon	0(0)	1 (0.4)	0.740
Corticosteroids	6 (20.8)	177 (77.6)	< 0.001
Remdesivir	1 (4.2)	58 (25.4)	0.016

Data are presented as n (%)
^aThe No Pneumonia group refers to the ambulatory group comprises no without presenting pneumonia –WHO 1
^bThe Pneumonia group comprises mild illness with pneumonia -WHO 2–7
^cNo Pneumonia and Pneumonia groups were compared using the non-parametric Mann–Whitney test for continuous data and √χ² test for categorical data. P-value < 0.05 was considered significant and marked in bold

ISSN: 2047-783X